Ouster to Present at November 2021 Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)-- Ouster, Inc. (NYSE: OUST) (“Ouster” or the “Company”), a leading provider of high-resolution digital lidar sensors for the automotive, industrial, smart infrastructure, and robotics industries, announced today that its CEO, Angus Pacala, and CFO, Anna Brunelle, will be presenting virtually at the following upcoming investor conferences.

Wolfe Research Industrial Growth & Technology Conference
Date: November 15, 2021
Presentation Time: 10:50 a.m. ET / 7:50 a.m. PT

12th Annual Craig-Hallum Alpha Select Conference
Date: November 16, 2021
1x1 Meetings Only

Barclays Global Automotive and Mobility Tech Conference
Date: November 17, 2021
Presentation Time: 3:55 p.m. ET / 12:55 p.m. PT

Barclays Global Technology, Media and Telecommunications Conference
Date: December 8-9, 2021
Presentation Time: TBD

To view the presentation webcasts, visit https://investors.ouster.com/events-and-presentations.

Please contact your Wolfe Research, Craig-Hallum, or Barclays sales representatives to request a one-on-one meeting with management at these events.

About Ouster

Ouster (NYSE: OUST) is a leading provider of high-resolution digital lidar sensors for the automotive, industrial, smart infrastructure, and robotics industries. Ouster products offer an excellent combination of price and performance and are built to a set of requirements that are flexible enough to span hundreds of use cases and enable revolutionary autonomy across industries. Ouster has approximately 600 customers in over 50 countries with offices in the Americas, Europe, Asia-Pacific and the Middle East. For more information, visit www.ouster.com, or connect with us on Twitter or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103006247/en/

For Investors
Sarah Ewing
[email protected]

For Media
Heather Shapiro
[email protected]

Source: Ouster, Inc.

You May Also Be Interested In

• Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Record Q2 Revenue, EAI Robotics Entering a Phase of Positive-Gross-Margin Volume Growth, and Accelerated Debt Reduction
• Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Ca
• Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs